DCISionRT uses tissue from a breast biopsy or surgery to provide an individualized risk profile based on your tumor biology. DCISionRT is intended to be used in conjunction with your physician’s standard workup to help make a personalized treatment recommendation.

Your biological profile is combined with clinical and pathologic risk factors using the DCISionRT algorithms to determine your individualized risk profile. This helps you and your physician understand your risk of recurrence over the next ten years.

DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?

Read DCIS 411 blog post: A New Bio-marker Test for DCIS = Peace of Mind for Thousands of Women